Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H10O4.2Na |
| Molecular Weight | 216.1421 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].CC\C(C([O-])=O)=C(/CC)C([O-])=O
InChI
InChIKey=GLJFFZOATODZQQ-XNOMRPDFSA-L
InChI=1S/C8H12O4.2Na/c1-3-5(7(9)10)6(4-2)8(11)12;;/h3-4H2,1-2H3,(H,9,10)(H,11,12);;/q;2*+1/p-2/b6-5-;;
| Molecular Formula | C8H10O4 |
| Molecular Weight | 170.1626 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:40:48 GMT 2023
by
admin
on
Sat Dec 16 11:40:48 GMT 2023
|
| Record UNII |
FDT5CJG2AD
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
929555-94-2
Created by
admin on Sat Dec 16 11:40:48 GMT 2023 , Edited by admin on Sat Dec 16 11:40:48 GMT 2023
|
PRIMARY | |||
|
16064853
Created by
admin on Sat Dec 16 11:40:48 GMT 2023 , Edited by admin on Sat Dec 16 11:40:48 GMT 2023
|
PRIMARY | |||
|
FDT5CJG2AD
Created by
admin on Sat Dec 16 11:40:48 GMT 2023 , Edited by admin on Sat Dec 16 11:40:48 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
ME1071 is a maleic acid that inhibits metallo-.BETA.-lactamases (MBLs). We examined its ability to potentiate different carbapenems against MBL-producing Enterobacteriaceae in relation to its inhibition kinetics. The key findings were: (i) the MICs of carbapenems varied widely among isolates with the same carbapenemase, but those with the NDM types were generally the most resistant; (ii) biapenem was the carbapenem least compromised by all MBL types, owing to weaker kinetic efficiency (k(cat)/K(m)) for hydrolysis, contingent on lower affinity (higher K(m)) (iii) MBLs were the only carbapenemases inhibited by ME1071, confirming its specificity of action
and (iv) irrespective of the partner carbapenem, synergy with ME1071 was least for organisms with NDM MBLs and most for those with IMP types, correlating with ME1071 having weakest affinity (highest K(i)) for NDM-1 and strongest affinity for IMP-1. ME1071 reduced the MICs of carbapenems for bacteria with NDM-1 enzyme though synergy was weaker than for bacteria with IMP and VIM metallo-enzymes; this correlated with ME1071 having weaker affinity for NDM-1 than IMP-1 and VIM-2. As the weakest MBL substrate carbapenem, biapenem was the easiest to protect.
|
||
|
ACTIVE MOIETY |
Originator: Meiji Seika Kaisha; Developer: Meiji Seika Pharma; Class: Small molecule; Mechanism of Action: Beta lactamase inhibitor; Highest Development Phases: Phase I for Gram-negative infections, Pseudomonal infections; Most Recent Events: 01 Apr 2011 Meiji Seika Kaisha is now called Meiji Seika Pharma, 28 Oct 2008 Antimicrobial data from in vitro studies presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008), 02 Oct 2007 Preclinical trials in Pseudomonal infections in Japan (Parenteral)
|
